Summary

This article reviews the main reasons why drugs fail in triple-negative breast cancer (TNBC) and targeted agents for the treatment of TNBC, as well as discusses ways that molecular triaging can assist in the selection of patients for clinical trials, the role of new cytotoxic agents in TNBC, and angiogenic vascular cells, infiltrating immune cells, and cancer-associated fibroblasts, and adipocytes as host components